Online inquiry

IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ253MR)

This product GTTS-WQ253MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EPCAM gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4072
UniProt ID P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ253MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4876MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ14215MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ3774MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ4179MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ15807MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ14451MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ3481MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ1308MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW